Endovia Health Sciences, Inc. filed Definitive Additional Materials on November 17, 2026, supplementing its proxy statement to correct the total voting power available at its 2026 Annual Meeting of Stockholders scheduled for November 20, 2026.

Key Highlights

  • Voting power corrected: Total voting power for the Annual Meeting was revised downward to 11,339,337 shares.
  • Series D excluded: The Company's Series D Convertible Preferred Stock was determined to be not entitled to vote at the Annual Meeting, prompting the correction.
  • Common stock outstanding: As of the October 2, 2026 record date, 11,079,337 shares of common stock were issued, outstanding, and entitled to vote.
  • Series A-1 voting rights: The 1,300 outstanding shares of Series A-1 Convertible Preferred Stock carry a total of 260,000 votes, representing 2.2% of outstanding voting power as of the original issuance date.
  • Series B also excluded: The 87,999 shares of Series B Convertible Preferred Stock are not entitled to vote at the Annual Meeting.
  • Reverse stock split in effect: All share and per-share figures reflect a one-for-four reverse stock split that took effect July 24, 2026, at 4:30 pm ET.
  • Quorum threshold: Holders of at least one-third of the 11,339,337 total voting power must be present in person or by proxy to conduct business at the meeting.

Endovia Health Sciences Corrects Proxy Voting Data Ahead of November 20 Annual Meeting

Endovia Health Sciences, Inc. (NYSE:EDVA), a health sciences company, filed this supplement to update information originally contained in its Definitive Proxy Statement filed with the SEC on October 5, 2026, and in Additional Definitive Materials filed on October 8, 2026. According to the filing, the correction was necessary because the Company's Series D Convertible Preferred Stock had been incorrectly treated as voting stock in earlier proxy materials. The supplement states that the Series D is not entitled to vote at the Annual Meeting, which reduced the total voting power figure disclosed to stockholders.

The filing replaced two specific questions and answers from the proxy statement, covering who is entitled to vote and what the quorum requirement is. As corrected, the record date of October 2, 2026 established that 11,079,337 shares of common stock were outstanding and entitled to one vote each. The 1,300 outstanding Series A-1 shares collectively carry 260,000 votes. The Series B Convertible Preferred Stock, with 87,999 shares outstanding, is similarly excluded from voting, alongside the Series D. The combined total voting power now stands at 11,339,337, according to the filing.

The supplement also notes that all share and per-share references in the proxy materials give effect to a one-for-four reverse stock split of the Company's issued, outstanding, and authorized shares, which became effective July 24, 2026, at 4:30 pm ET. The quorum requirement, as stated in the filing, requires holders of at least one-third of the total outstanding voting power to be present at the Annual Meeting in person or represented by proxy in order to conduct business.

What Was Disclosed

Endovia Health Sciences filed supplemental proxy materials to correct its disclosed total voting power for its November 20, 2026 Annual Meeting, reducing the figure to 11,339,337 after clarifying that Series D Convertible Preferred Stock does not carry voting rights at that meeting.